Thursday, June 09, 2011
abstract & full free access: Impact of tumour volume on the potential efficacy of therapeutic vaccines | Gulley | Current Oncology
Impact of tumour volume on the potential efficacy of therapeutic vaccines
J.L. Gulley, MD PhD*, R.A. Madan, MD*, J. Schlom, PhD*
*Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
With the recent approval by the U.S. Food and Drug Administration of the first therapeutic vaccine for cancer, the long-awaited goal of harnessing a patient’s immune system to attack cancer through this modality is finally realized. However,
1) What’s New:
Current Oncology showcases art, from the ART for Cancer Group
Cancer Charities Supported (click)
"....A meta-analysis of 18 studies of women who had been exposed to asbestos through their work was carried out. Earlier studies failed to prove the link because of concerns that tumours had been mis-classified - until recently it was difficult to discriminate between peritoneal mesothelioma and ovarian cancer...."